The company's financial position has deteriorated significantly, with total equity falling to a negative $2.8 million and total debt rising to $4.8 million as of 2026Q1.
| Total Current Assets | 3.41M | 4.82M | 4.65M | 28.74K | 69.66K | 454.67K | 549.98K | 4.97K |
| Cash & Short-Term Investments | 2.36M | 3.79M | 3.77M | 28.48K | 64.43K | 330.6K | 208K | 1.28K |
| Cash Only | 2.36M | 3.79M | 3.77M | 28.48K | 64.43K | 330.6K | 208K | 1.28K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 126.23K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | 40.91 | - |
| Inventory | 148.07K | 159.79K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 6.44K | 13.78K | - | - | - | - | - | - |
| Other Current Assets | 899.36K | 875.85K | 114.09K | 261 | 5.23K | 124.07K | 215.75K | 3.69K |
| Total Non-Current Assets | 538.4K | 739.05K | 1.55M | 119.85K | 166.28K | 212.71K | 0 | 1.21K |
| Property, Plant & Equipment | 11.61K | 23.21K | 69.64K | 116.07K | 162.5K | 208.93K | 0 | 0 |
| Fixed Asset Turnover | 1.39x | 0.94x | - | - | 1.44x | 3.05x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 500K | 0 |
| Other Non-Current Assets | 526.8K | 715.84K | 1.48M | 3.78K | 3.78K | 3.78K | -500K | 1.21K |
| Total Assets | 3.95M | 5.56M | 6.2M | 148.59K | 235.94K | 667.38K | 549.98K | 6.18K |
| Asset Turnover | 0.01x | 0.00x | - | - | 0.99x | 0.96x | 2.05x | - |
| Asset Growth % | 5682.52% | -10.29% | 4074.12% | -37.02% | -64.65% | 21.35% | 8803.72% | - |
| Total Current Liabilities | 6.73M | 7.4M | 2.01M | 5.77M | 7.26M | 5.68M | 4.26M | 5.02M |
| Accounts Payable | 0 | 0 | 278.68K | 189.5K | 187.03K | 256.89K | 252.19K | 131.05K |
| Days Payables Outstanding | 19.74K | - | - | - | - | - | - | - |
| Short-Term Debt | 4.83M | 5.32M | 146.43K | 2.02M | 1.73M | 440.61K | 108.48K | 1.21M |
| Deferred Revenue (Current) | 735 | 735 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.9M | 2.08M | 118.87K | 3.07M | 4.91M | 4.53M | 3.34M | 3.68M |
| Current Ratio | 0.51x | 0.65x | 2.31x | 0.00x | 0.01x | 0.08x | 0.13x | 0.00x |
| Quick Ratio | 0.48x | 0.63x | 2.31x | 0.00x | 0.01x | 0.08x | 0.13x | 0.00x |
| Cash Conversion Cycle | -13.3K | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 21.25K | 178.04K | 119.54K | 164.4K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 106.71K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 21.25K | 71.33K | 119.54K | 164.4K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 6.73M | 7.4M | 2.03M | 5.95M | 7.38M | 5.85M | 4.26M | 5.02M |
| Total Debt | 4.83M | 5.32M | 217.76K | 2.25M | 1.9M | 651.2K | 108.48K | 1.21M |
| Net Debt | 2.47M | 1.53M | -3.55M | 2.22M | 1.83M | 320.6K | -99.52K | 1.21M |
| Debt / Equity | -1.74x | - | 0.05x | - | - | - | - | - |
| Debt / EBITDA | -0.54x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.27x | - | - | - | - | - | - | - |
| Interest Coverage | -76.77x | -129.94x | -8.82x | -20.87x | -5.69x | -35.85x | -121.25x | -8.61x |
| Total Equity | -2.78M | -1.83M | 4.17M | -5.8M | -7.14M | -5.18M | -3.71M | -5.02M |
| Equity Growth % | -108.71% | -143.91% | 171.91% | 18.8% | -37.98% | -39.52% | 26.02% | - |
| Book Value per Share | -0.08 | -0.05 | 0.14 | -0.18 | -0.22 | -0.55 | -0.42 | -0.57 |
| Total Shareholders' Equity | -2.78M | -1.83M | 4.17M | -5.8M | -7.14M | -5.18M | -3.71M | -5.02M |
| Common Stock | 3.63K | 3.44K | 3.31K | 2.65K | 2.64K | 653 | 627 | 553 |
| Retained Earnings | -36.73M | -34.67M | -26.02M | -23.58M | -18.8M | -13.84M | -9.64M | -7.99M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and dilution
As reported in recent financial filings, Jupiter Neurosciences has seen its total equity plummet to a negative $2.8 million in 2026Q1, a stark deterioration from the positive $3.1 million position held in 2025Q1, signaling a trajectory of rapid capital depletion driven by persistent, unmitigated operational losses.
The consistent decline in net assets suggests that the company is consuming its capital base faster than it can replenish it through financing. This trend indicates that the business model is currently unsustainable without continuous, dilutive external capital injections.
Based on the company's latest balance sheet, total debt has climbed to $4.8 million as of 2026Q1, representing a significant portion of the firm's $3.9 million in total assets, which suggests that debt is being utilized as a necessity-driven lifeline rather than a strategic growth tool.
The reliance on debt in a pre-revenue state creates substantial refinancing risk and places pressure on future cash flows. Investors should monitor whether these obligations contain restrictive covenants that could further limit the company's operational flexibility during critical trial phases.
According to quarterly data, the current ratio has compressed to 0.51 in 2026Q1, down from 2.31 in 2024Q4, indicating that the company's ability to cover short-term liabilities with liquid assets is severely compromised and warrants immediate concern regarding the firm's ongoing viability.
A current ratio below 1.0 suggests that current liabilities exceed current assets, leaving little room for error in managing clinical trial expenses. This liquidity profile implies that the company may face significant challenges in meeting its near-term obligations without securing additional funding.
As evidenced by the company's financial statements, retained earnings have deepened to a negative $36.7 million as of 2026Q1, reflecting a persistent history of value destruction that has pushed total equity into negative territory and highlights the extreme dilution risk facing current shareholders.
The negative equity position suggests that the company has exhausted its initial capital and is now operating on borrowed funds or through highly dilutive equity raises. This structure makes the stock highly sensitive to any news that could impact the valuation of its clinical pipeline.
Based on reported figures, the company's asset base is almost entirely devoid of tangible value, with net PPE of only $11.6K in 2026Q1, which suggests that the firm's valuation is tied exclusively to intangible clinical prospects rather than any underlying physical or productive infrastructure.
The lack of meaningful tangible assets means that in a liquidation scenario, there is virtually no recovery value for stakeholders. This underscores the binary nature of the investment, where the balance sheet provides no safety net should the clinical trials fail to meet their primary endpoints.
Quick answers to the most common questions about buying JUNS stock.
As of 2025, Jupiter Neurosciences, Inc. (JUNS) had total assets of $5.6M including $4.8M in current assets.
Jupiter Neurosciences, Inc. (JUNS) carries total debt of $5.3M, offset by $3.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Jupiter Neurosciences, Inc. (JUNS) has total shareholders' equity (book value) of $-1.8M ($-0.05 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Jupiter Neurosciences, Inc. (JUNS) reported a current ratio of 0.65x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.